h2o Therapeutics and AmerisourceBergen partner on Parkinson's disease app

Digital health company, h2o therapeutics, has announced a collaboration with global healthcare company AmerisourceBergen to support the commercialisation of Parky, it’s Parkinson’s Disease focused prescription mobile app. 

The app, which received FDA 510(k) clearance last year, utilises the Apple Watch to monitor an individual's Parkinson’s Disease symptoms such as tremors or dyskinesia in real time.  The tool includes medication reminders as well as a portal that allows for sharing of data between a patient and medical professionals. The Parky app aims to support healthcare providers to develop a profile of patients' daily lives, helping to close the gap between clinical and real life settings. 

As part of a pilot arrangement, AmerisourceBergen will support patient engagement and health systems integration through its DTx Connect platform. The cloud-based platform allows for ordering, dispensing, and fulfilling physician-ordered digital therapeutics and diagnostics. 

"Following the recent FDA clearance, we continue to focus on strategies and solutions that will enable us to expand patient access to Parky," Yagmur Selin Gulmus, founder of h2o Therapeutics, said in a statement. "Through this arrangement with AmerisourceBergen, our goal is to reduce barriers along the patient journey, improve access and expand our commercial reach."

Click here to read the original news story.